A somatic EZH2 mutation in childhood acute myeloid leukemia

Leukemia

Volumn 26, Issue 7, 2012, Pages 1701-1703

  Ernst, T ^a   Pflug, A ^a   Rinke, J ^a   Ernst, J ^a   Bierbach, U ^b   Beck, J F ^a   Hochhaus, A ^a   Gruhn, B ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CEBPA PROTEIN; CYTARABINE; DNA METHYLTRANSFERASE 3A; ETOPOSIDE; GENOMIC DNA; HISTONE METHYLTRANSFERASE; ISOCITRATE DEHYDROGENASE 1; MICROSOMAL AMINOPEPTIDASE; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; CYTOGENETICS; DNA METHYLATION; DRUG MEGADOSE; EPIGENETICS; EXON; GENE FUNCTION; GENETIC ASSOCIATION; HEPATOSPLENOMEGALY; HUMAN; INTRON; KARYOTYPE; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PROGNOSIS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84863781377     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.16     Document Type: Letter

References (15)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29: 551-565.
2. Langemeijer SM, Jansen JH, Hooijer J, van Hoogen P, Stevens-Linders E, Massop M et al. TET2 mutations in childhood leukemia. Leukemia 2011; 25: 189-192.
3. Thol F, Heuser M, Damm F, Klusmann JH, Reinhardt K, Reinhardt D. DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica 2011; 96: 1238-1240.
4. Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children0s Oncology Group. Pediatr Blood Cancer 2011; 57: 204-209.
5. Pigazzi M, Ferrari G, Masetti R, Falini B, Martinolli F, Basso G et al. Low prevalence of IDH1 gene mutation in childhood AML in Italy. Leukemia 2011; 25: 173-174.
6. Oki K, Takita J, Hiwatari M, Nishimura R, Sanada M, Okubo J et al. IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. Leukemia 2011; 25: 382-384.
7. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13-27.
8. WoutersBJ, Jordà MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007; 110: 3706-3714.
9. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
10. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
11. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z et al. Novel homo-and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24: 1799-1804.
12. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
13. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846-856.
14. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
15. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042.